On placental and lactational transfer of IgG‐based therapeutic proteins – Current understanding and knowledge gaps from a clinical pharmacology perspective
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Daphne Guinn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver S…. Hauptthemen laut MEDLINE: Immunoglobulin G, Lactation, Placenta, Maternal-Fetal Exchange. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Maternal medication use may expose the developing fetus through placental transfer or the infant through lactational transfer. Because pregnant and lactating individuals have been historically excluded from early drug development trials, there is often limited to no human data available to inform pharmacokinetics (PK) and safety in these populations at the time of drug approval. We describe the known mechanisms of placental or lactational transfer of IgG‐based therapeutic proteins and use clinical examples to highlight the potential for fetal or infant exposure during pregnancy and lactation. Placental transfer of IgG‐based therapeutic proteins may result in systemic exposure to the developing fetus. A lactational transfer may be associated with local gastrointestinal (GI) exposure in the infant and may also result in systemic exposure, although data are very limited as proteins have shown instability in the GI tract. Understanding of PK and pharmacodynamic (PD) effects of IgG‐based therapeutic proteins in infants exposed in utero as well as the potential exposure through human milk and its clinical implications is critical for developing treatment strategies for pregnant or lactating individuals. We share the current knowledge gaps and considerations for future evaluations to inform PK, PD, and the safety of IgG‐based therapeutic proteins for safe use during pregnancy and lactation. With the increasing use of IgG‐based therapeutic proteins in treating chronic diseases during pregnancy and lactation, there is a need to improve the quantity and quality of data to inform the safe use in pregnant and lactating individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Division of Pediatrics and Maternal Health, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silve…
ORCID-Profile: Yow-Ming Wang
Zitieren
APA
Guinn, D., Kratz, K., Baisden, K., Ridge, S., McClymont, S., Fletcher, E. P., Johnson, T., & Wang, Y. M. (2024). On placental and lactational transfer of IgG‐based therapeutic proteins – Current understanding and knowledge gaps from a clinical pharmacology perspective. Clinical and Translational Science. https://doi.org/10.1111/cts.70049
Vancouver
Guinn D, Kratz K, Baisden K, Ridge S, McClymont S, Fletcher EP, et al. On placental and lactational transfer of IgG‐based therapeutic proteins – Current understanding and knowledge gaps from a clinical pharmacology perspective. Clinical and Translational Science. 2024. doi:10.1111/cts.70049
BibTeX
@article{Guinn2024,
author = {Guinn, Daphne and Kratz, Katherine and Baisden, Kristie and Ridge, Sarah and McClymont, Sonaly and Fletcher, Elimika Pfuma and Johnson, Tamara and Wang, Yow-Ming},
title = {On placental and lactational transfer of IgG‐based therapeutic proteins – Current understanding and knowledge gaps from a clinical pharmacology perspective},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70049}
}
EUVIMED